Considering the knowledge that the anti-tumor activity of CCR8 antibodies depends on their ADCC ability, a more promising future avenue for the development of CCR8-targeting small molecule candidates for cancer treatment may lie in the creation of small molecule drug conjugates (SMDCs) capable of selectively targeting and eliminating CCR8-expressing TITRs, which are prevalent in diverse tumor types. Here, CCR8 is linked to cancer.